News

From Staff Reports Copyright © 2015 The Oklahoma Publishing Co. i2E Inc. and Accele Venture Partners recently closed a $600,000 follow-on investment in Synereca Pharmaceuticals, a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator. With the most recent investment, Synereca has now received $2.5 million in funding to support its development of compoundsRead more

i2E and Accele Venture capital recently lead a $2.2 million investment in Pamilco Biopharma. i2E invested t through its Oklahoma Seed Capital Fund.

i2E, Inc., and Accele Venture Partners recently closed a $2.2 million investment in Pamlico Biopharma, Inc., a portfolio company of Accele Biopharma, an Oklahoma City-based biotechnology accelerator.

Synereca Pharmaceuticals has received $1.4 million in seed capital from i2E Inc. The Oklahoma City-based company is developing a compound that kills drug resistant bacteria.

i2E, Inc., recently closed on a $1.4 million seed capital investment in Oklahoma City-based Synereca Pharmaceuticals, which is developing ground-breaking compound that kills drug resistant bacteria.